Zuyderland Medisch Centrum Stichting — Clinical Trial Site

136 Registered trials

56 Currently recruiting

Organisation

Zuyderland Medisch Centrum Stichting

Location

Heerlen, Netherlands

Identifier

ORG-100023231

Address

Henri Dunantstraat 5, 6419 PC, Netherlands

Departments

#3356:Cardiology
#3719: Cardiology
#6001:Neurology
3024: Neurology
3719: Cardiology
5004:Pulmonology
7003: Rheumatology
Academisch MS Centrum Zuyderland
Atrium MC loc. Heerlen, dept. Internal medicine
Cardiology
Cardiology department
Dep of Cardiology
Department of Neurology
Department of Oncology
Department of orthopedic surgery
Department of pulmonology
Department of Respiratory Medicine
Department of Surgery
Dermatology
Endocrinologie
Gastroenterology
Gastroenterology, Geriatrics & Internal and Intensive Medicine
gynaecologie
Gynaecology
Hematologie
Hematology
ICU
Internal Medicine
Internal Medicine - Hematology
Internal Medicine / Oncology
Internal Medicine and Oncology
Internal Medicine, Medical Oncology
Internal Medicine/oncology
interne geneeskunde
Longgeneeskunde
Longoncologie
Lung disease
MDL
Medical oncology
Medische Oncologie
N/A
Neurologie
Neurology
Neurosurgery
Not applicable
Obstetrics & Gynecology
Oncology
Orthopedic surgery
Pulmonary diseases
Pulmonary medicine
Pulmonary Science
Pulmonology
R&D Longziekte
R&D Longziekten
Reproductive medicine and gynecology
Rhematology
Rheumatology
Stichting Zuyderland Medisch Centrum
Surgery
urology
Zuyderland Medisch Centrum
Zuyderland Medisch Centrum Stichting
Zuyderland Medisch Centrum( #1)
Zuyderland ziekenhuis
Zuyderland ziekenhuis_LOC#1

Clinical trials at this site (136)

Search interface

A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised

2023-503631-18-00 Nervous system diseases 5
Sarilumab efficacy and safety in adults with early polymyalgia rheumatica Pending

2024-511296-15-00 Musculoskeletal diseases 5
Avelumab Short Maintenance Trial Pending

2024-512975-11-01 urothelial cancer 11
A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending

2024-514246-37-00 Idiopathic pulmonary fibrosis (IPF) 4
Applying Mysimba in patients with weight regain after bariatric surgery Pending

2024-516645-39-01 Obesity 11
OCEAN(a)-PreEvent - Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction to Prevent first major cardiovascular Events Pending

2025-520554-11-00 Cardiovascular Disease 5
A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending

2025-522373-10-00 Progressive pulmonary fibrosis and Idiopathic pulmonary 5
Adjuvant Pembrolizumab in patients with early-stage triple negative breast cancer with residual disease after treatment with chemotherapy an… Pending

2025-524229-41-00 Triple negative breast cancer 5
HO182 CLL: Treatment of patients with chronic lymphocytic leukemia (CLL) with 6 cycles of rituximab in combination with 6 or 26 cycles of ve… Pending

2025-524283-38-00 Relapsed or refractory chronic lymphocytic leukemia 5
A Phase 3 Study of Orelabrutinib in Non-active Secondary Progressive Multiple Sclerosis Pending

2025-524322-18-00 Non-active Secondary Progressive Multiple Sclerosis (SP 5
Does progesterone luteal‑phase support increase live birth rates in couples with unexplained infertility assigned to expectant management? Pending

2026-525747-33-00 unexplained subfertillity, infertillity 6
A Phase 3 Study of Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis Recruiting

2025-524316-11-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2026-06-11
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma (SOLAIRIA-1) Recruiting

2025-521950-41-00 severe uncontrolled asthma 5 2026-06-05
An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting

2024-519870-38-00 Atherosclerotic cardiovascular disease (ASCVD) 5 2026-05-11
Study for frail patients with newly diagnosed multiple myeloma treated with Daratumumab in combination with Teclistamab and Talquetamab. Recruiting

2024-520433-76-00 Newly Diagnosed Multiple Myeloma 4 2026-01-08
T3-4-Hypo trial Recruiting

2024-513883-24-00 Hypothyroidism Triiodothyronine Quality of Life Persist 5 2025-11-02
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting

2024-512753-24-00 Acute Myeloid Leukemia (AML) 5 2025-08-05
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis Recruiting

2023-503699-25-00 Progressive Pulmonary Fibrosis 5 2024-07-15
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting

2023-503697-21-01 Idiopathic pulmonary fibrosis 5 2024-06-24
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting

2022-501893-21-00 Acute myocardial infarction 4 2022-05-03
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28